New study reveals "enormous medical value" of Lundbeck's new migraine drug compared to generics, Head of R&D says

Lundbeck's migraine treatment Vyepti is more expensive than traditional treatment options, which are available as generic drugs, but EVP and Head of R&D Johan Luthman says recently publicized phase III data supports the pricing assessment for the drug.
Photo: PR / Lundbeck
Photo: PR / Lundbeck
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Lundbeck's newest study of migraine therapy vyepti will not result in new indications for the drug or expand the enclosed patient information leaflet in any major way. Nonetheless, Head of Research and Development at Lundbeck Johan Luthman is pleased about the results.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading